Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Probaclac in Irritable Bowel Syndrome in Children Aged 8 to 18 Years

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children 8 to 18 years~* Irritable bowel syndrome according to Rome III criteria~Exclusion Criteria:~* Not able to collaborate~* Known Digestive malformation~* History of digestive surgery (except hernia repair and appendectomy)~* History of known digestive disease (Crohn's, ulcerative colitis, esophagitis, peptic ulcer, celiac disease)~* Symptoms suggestive of organic disease (such as rectal bleeding, weight loss~* History of chronic extra-digestive disease~* Acute gastroenteritis in th e4 weeks prior to inclusion~* Central catheter, artificial cardiac valve, endocardiac prothesis~* Current Antidepressant treatment~* Patients taking a treatment for irritable bowel syndrome unable to cease their current treatment~* Patient taking regularly probiotics and natural products

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Probaclac (Type: EXPERIMENTAL): Administration of Bifidobacterium bifidum R0071, Bifidobacterium longum R0175, Lactobacillus helveticus R0052, Lactobacillus Delb. SSP bulgaricus R9001, Lactobacillus rhamnosus R0011, Lactococcus Lactis SSP. lactis R1058 et Streptococcus thermophilus (Probaclac™) b.i.d.
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).